Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

This study aimed to identify the effects of OM-85 BV in patients with chronic obstructive pulmonary disease (COPD). PubMed, Embase, CINAHL, and ClinicalTrials.gov were searched for eligible randomized controlled trials (RCTs). The major end point was exacerbation rate, and the minor end points included duration of hospitalization, severity of acute exacerbation, incidence rate of patients using antibiotics, and adverse events. All data were derived with relative risks (RRs) and weighted mean differences. Five RCTs with 1190 patients were enrolled in the meta-analysis. OM-85 BV was associated with 20% and 39% reductions in exacerbation rate (RR, 0.80; 95% confidence interval [CIs], 0.65-0.97; P = .03) and incidence rate of patients using antibiotics (RR, 0.61; 95%CI, 0.48-0.77; P < .0001) compared with the placebo. However, OM-85 BV was not significantly associated with duration of hospitalization, severity of acute exacerbation, and total adverse events. Current evidence supporting the benefits of OM-85 BV to COPD patients is inadequate. Further larger-scale trials must be conducted to validate our findings and the efficacy of OM-85 BV in COPD patients. © 2015, The American College of Clinical Pharmacology.

Citation

Lei Pan, Xue-Ge Jiang, Jun Guo, Yuan Tian, Chang-Ting Liu. Effects of OM-85 BV in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis. Journal of clinical pharmacology. 2015 Oct;55(10):1086-92

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 25903441

View Full Text